Intellia Therapeutics
NTLANASDAQExtreme RiskPioneering in vivo CRISPR gene editing — delivering CRISPR components directly into a patient's body via lipid nanoparticles, rather than editing cells outside the body. This enables one-time IV infusions that can permanently edit genes in the liver and potentially other organs.
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
Market cap
Mid cap
Cash position
$628M as of Q2 2026
~19 months runway (derived)
Revenue status
pre revenue
Pipeline assets
2 programs
What does Intellia Therapeutics do?
Intellia Therapeutics is trying to do something no company has ever done: prove that you can safely edit a person's genes while they're still inside their body. Most gene editing therapies (like CRISPR Therapeutics' Casgevy) work by taking cells OUT of a patient, editing them in a lab, and putting them back. Intellia's approach is radically different: they package CRISPR gene-editing tools inside tiny fat particles (lipid nanoparticles), inject them into a vein, and the particles travel to the liver where they permanently cut and disable a disease-causing gene. Their most advanced program targets a disease called transthyretin amyloidosis (ATTR), where the liver makes a misfolded protein that accumulates in the heart and nerves, eventually causing heart failure. Current treatments require lifelong injections every few weeks. Intellia's approach: one IV infusion that permanently stops the liver from making the bad protein. In Phase 1, a single dose reduced the disease protein by 93% — and the effect has lasted over two years so far. They're running the same playbook with hereditary angioedema (HAE), a condition causing severe, unpredictable swelling episodes. One infusion to knock out the gene responsible, potentially ending the disease permanently. For investors, 2026 is make-or-break: both Phase 3 programs should report interim data. Success would make Intellia the first company to prove in vivo CRISPR works in pivotal trials — a truly historic achievement. But the risks are real: a patient death in the ATTR trial shook confidence, and the company is burning cash fast with no revenue.
What to watch
HAE Phase 3 interim data is likely the first catalyst — look for attack rate reduction consistent with the 95% seen in Phase 1/2
ATTR Phase 3 interim data — TTR protein reduction should be >90% to match earlier results. Any safety signals will be heavily scrutinized
FDA feedback on whether interim data could support accelerated approval for either program
Cash burn trajectory relative to remaining runway — any hint of a capital raise will pressure the stock
Competitor data from Alnylam (HELIOS-B for ATTR) and Ionis (ATTR-CM program) that sets the bar NTLA-2001 must clear
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| NTLA-2001 (nexiguran ziclumeran) | Transthyretin amyloidosis (ATTR) — hereditary and wild-type | Phase 3 | Not disclosed | ▼ |
| NTLA-2002 | Hereditary angioedema (HAE) | Phase 3 | Phase 3 interim early 2026 | ▼ |
Investment thesis
Bull case
Intellia is the leader in in vivo CRISPR gene editing — the ability to edit genes inside a living person with a single IV infusion. NTLA-2001 Phase 1 data showing 93% TTR reduction sustained for years is arguably the most impressive clinical result in gene editing history. Two Phase 3 programs (ATTR and HAE) could both read out in 2026, creating a double-catalyst setup. If either succeeds, it validates an entirely new therapeutic modality. The ATTR market alone is $5B+ and growing as diagnosis rates improve. A one-time cure vs. lifelong repeat dosing is an obvious patient and payer preference. Intellia is the first company that could prove in vivo CRISPR works in large trials.
Bear case
Intellia took a devastating hit when a patient died in the NTLA-2001 trial, causing the Phase 3 to be modified with enhanced monitoring. Even if the death was unrelated to the drug, it creates regulatory scrutiny and investor anxiety. The $120M quarterly burn is aggressive for a pre-revenue company with $1.1B in cash — runway is about 2.5 years. If either Phase 3 disappoints, they'll need to raise capital at what could be depressed levels. The permanent nature of gene editing means any safety signal is permanent too — you can't un-edit a gene. RNA-based competitors like Alnylam offer a reversible alternative that regulators and patients may prefer. And Intellia has already burned through $2B+ since inception with zero approved products.
Key upcoming catalysts
Potential accelerated approval filing for NTLA-2002 in HAE
H2 2026
Unverified — this date has not been checked against a primary source.
OPB-601 (ex vivo CAR-T) Phase 1/2 data update
2026
Unverified — this date has not been checked against a primary source.
Risk factors
Patient death in NTLA-2001 trial creates lasting regulatory and perception overhang
Phase 3 interim analysis in HAE or ATTR could fail to meet primary endpoints
Permanent nature of gene editing means any long-term safety issues are irreversible
Alnylam's repeat-dosing RNA approach may be preferred by regulators as the safer path
Cash runway of ~2.5 years forces capital raise if trials are delayed or fail
Comparable companies
Financial snapshot
These figures are drafted by our AI pipeline, not read from SEC filings. Confirm anything you would act on against the company's latest 10-Q or 10-K.
Cash
$628M as of Q2 2026
Q2 2026 — 1 quarter ago
Quarterly burn
$100M
Cash runway
~19 months
$628M ÷ $100M per quarter
Revenue
pre revenue
Institutional ownership
78%
Source: SEC filings. Cash and operating cash flow read from NTLA’s SEC XBRL filings, most recently filed 2026-08-06. Read the filings on EDGAR.
Sponsored
Get premium NTLA analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you